Study: Stroke Prevention Results No Stronger Than Aspirin
A new study indicates that Xarelto stroke prevention outcomes may not be as positive as previously thought.
The study identifies that the side effects of Xarelto may include significant bleeding risks but that stroke prevention may not be successful in patients who are taking it for that purpose.
The research study found that Xarelto was no more effective at preventing strokes when compared with aspirin with regard to preventing a second stroke for patients who have already sustained one.
Canadian researchers identified that Xarelto stroke prevention may be a positive outcome associated with taking the medication, but it may not be a superior alternative when compared with Aspirin.
Comparatively, the users of Xarelto may experience significant and painful side effects. The research of the Xarelto stroke prevention study were recently published in the New England Journal of Medicine, indicating that the study ultimately had to be cancelled due to the high risk of bleeding events.
Xarelto is a popular and leading member of a new generation of medications known as direct oral anticoagulants.
These medications are often marketed as superior to the long relied upon Warfarin for the prevention of blood clots linked to atrial fibrillation and other conditions. The blood thinning effects of Warfarin can easily be reversed with plasma and vitamin K, but many new blood thinners like Xarelto were not released with a reversal agent.
Thousands of reported injuries and serious bleeding events have been reported despite the fact that the manufacturer still continues to claim that the benefits of Xarelto stroke prevention were high. In this particular study however, the study looked at the safety and effectiveness of Xarelto in a clinical trial that involved more than 7,000 patients.
More than 3,600 of those patients received a 50mg daily dose of Xarelto and another 3,600 were given a 100mg daily dose of aspirin.
The patients were followed for 11 months but the study was ultimately cancelled due to the lack of ‘s effectiveness and the high bleeding risks.
The risk of recurrent stroke in those patients getting the two drugs was the same at 4.7 percent but for those patients given Xarelto , 1.8 percent suffered major bleeding events compared with only 0.7 percent of those in the aspirin group.
Three months previously, another set of Canadian researchers identified that Xarelto was no more effective than aspirin at preventing blood clots.
Xarelto stroke prevention may be one common reason why a person considers taking the medication after it is recommended by their doctor but the side effects can be serious particularly if a bleeding event occurs.
Those patients who sustained a bleeding event may be eligible to pursue legal action against a manufacturer. Many previous plaintiffs who have already sustained a bleeding event or who have lost a loved one because of an unexpected bleeding event have filed legal action and accused a manufacturer of failing to warn.